Publications

  1. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. Kefalopoulou Z, Politis M, Piccini P, Mencacci N, Bhatia K, Jahanshahi M, Widner H, Rehncrona S, Brundin P, Björklund A, Lindvall O, Limousin P, Quinn N, Foltynie T. JAMA Neurol. 2014 Jan;71(1):83-7.
  2. Transcriptional changes in organoculture of full-thickness human skin following topical application of all-trans retinoic acid. Gillbro JM, Al-Bader T, Westman M, Olsson MJ, Mavon A. Int J Cosmet Sci. 2014 Jun;36(3):253-61. doi: 10.1111/ics.12121. Epub 2014 Mar 27.
  3. The melanogenesis and mechanisms of skin-lightening agents–existing and new approaches. Gillbro JM, Olsson MJ. Int J Cosmet 2011 Jun;33(3):210-21. doi: 10.1111/j.1468-2494.2010.00616.x. Epub 2011 Jan 25.
  4. Serotonergic neurons mediate dyskinesia side effects in Parkinson’s patients with neural transplants. Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Rehncrona S, Bjorklund A, Lindvall O, Piccini P.  Sci Transl Med. 2010 Jun 30;2(38):38ra46.
  5. Vitiligo. Olsson MJ. Published 2010 by Springer, Tiergartenstr. 17, 69121 Heidelberg, Germany, ISBN: 978-3-540-69360-4.
  6. Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson’s disease. Li JY, Englund E, Widner H, Rehncrona S, Björklund A, Lindvall O, Brundin P. Mov Disord. 2010 Jun 15;25(8):1091-6.
  7. Transcriptional profiling of melanocytes from patients with vitiligo vulgaris. Sara Strömberg, Marcus Gry Björklund, Fredrik Pontén, Joakim Lundeberg, Peter Nilsson, Anna Asplund and Mats J. Olsson. Pigment Cell and Melanoma Research 2008; 21 (2): 162-171.
  8. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Björklund A, Widner H, Revesz T, Lindvall O, Brundin P. Nat Med. 2008 May;14(5):501-3.
  9. Surgical Management of Vitiligo. Mats J. Olsson. published 2007 by Blackwell Publishing Ltd, 9600 Garsington Road, Oxford OX4 2DQ, UK, ISBN: 978-1-4051-4521-3.
  10. The vitiligo clinic at the Department of Dermatology, Akademiska sjukhuset in Uppsala. Håkan Hedstrand and Mats J. Olsson. Forum for Nordic dermato-venereology 2006; No.1, Vol.11: 5-8.
  11. What Are the Needs for Transplantation Treatment in Vitiligo, and How Good Is It? (Editorial). Olsson MJ. Arch Dermatol Oct 2004; 140: 1273-74.
  12. Vitiligo and Piebaldism. Olsson MJ. Forum for Nord Derm Ven 2002; No.2, Vol.7: 18-20.
  13. Dyskinesias following neural transplantation in Parkinson’s disease. Hagell P, Piccini P, Björklund A, Brundin P, Rehncrona S, Widner H, Crabb L, Pavese N, Oertel WH, Quinn N, Brooks DJ, Lindvall O. Nat Neurosci. 2002 Jul;5(7):627-8.
  14. Long-term follow-up of leucoderma patients treated with transplants of autologous cultured melanocytes, ultrathin epidermal sheets and basal cell layer suspension. Olsson MJ, Juhlin L. Br J of Dermatology 2002; 147: 893-904.
  15. Vitiligo and Piebaldism. Treatment of Leucoderma by Transplantation of autologous melanocytes. Olsson MJ. Acta Universitatis Upsaliensis. Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1061. 77 pp. Uppsala. ISBN 91-554-5080-6: 2001.
  16. The transcription factors SOX9 and SOX10 are melanocyte autoantigens related to vitiligo in autoimmune polyendocrine syndrome type I. Hedstrand H, Ekwall O, Olsson MJ, et al. J of Biological Chemistry 276; 35390-3535395: 2001.
  17. Delayed recovery of movement-related cortical function in Parkinson’s disease after striatal dopaminergic grafts. Piccini P, Lindvall O, Björklund A, Brundin P, Hagell P, Ceravolo R, Oertel W, Quinn N, Samuel M, Rehncrona S, Widner H, Brooks DJ. Ann Neurol. 2000 Nov;48(5):689-95.
  18. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson’s disease. Brundin P, Pogarell O, Hagell P, Piccini P, Widner H, Schrag A, Kupsch A, Crabb L, Odin P, Gustavii B, Björklund A, Brooks DJ, Marsden CD, Oertel WH, Quinn NP, Rehncrona S, Lindvall O. Brain. 2000 Jul;123 ( Pt 7):1380-90.
  19. Dopamine release from nigral transplants visualized in vivo in a Parkinson’s patient. Piccini P, Brooks DJ, Björklund A, Gunn RN, Grasby PM, Rimoldi O, Brundin P, Hagell P, Rehncrona S, Widner H, Lindvall O. Nat Neurosci. 1999 Dec;2(12):1137-40.
  20. Sequential bilateral transplantation in Parkinson’s disease: effects of the second graft. Hagell P, Schrag A, Piccini P, Jahanshahi M, Brown R, Rehncrona S, Widner H, Brundin P, Rothwell JC, Odin P, Wenning GK, Morrish P, Gustavii B, Björklund A, Brooks DJ, Marsden CD, Quinn NP, Lindvall O. Brain. 1999 Jun;122 ( Pt 6):1121-32.
  21. A Serotonin-like Immunoreactivity is Present in Human Cutaneous Melanocytes. Johansson O, Liu P-Y, Bondesson L, Nordlind K, Olsson MJ, Löntz W, Verhofstad A, Liang Y and Gangi S. J of Invest Dermatol 111; 1010-14: 1998 .
  22. Leukoderma treatment by transplantation of a basal cell layer enriched suspension. Olsson MJ, Juhlin L. Br J of Dermatology 1998; 138: 644-648.
  23. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson’s disease. Wenning GK, Odin P, Morrish P, Rehncrona S, Widner H, Brundin P, Rothwell JC, Brown R, Gustavii B, Hagell P, Jahanshahi M, Sawle G, Björklund A, Brooks DJ, Marsden CD, Quinn NP, Lindvall O. Ann Neurol. 1997 Jul;42(1):95-107.
  24. A critical review of the current status and possible developments in brain transplantation. Rehncrona S. Adv Tech Stand Neurosurg. 1997;23:3-46.
  25. Differential uptake of chloroquine by human keratinocytes and melanocytes in culture. Sjölin-Forsberg G, Berne B, Johansson M, Olsson MJ, Rollman O. Arch Dermatol Res 1996; 288: 211-215.
  26. Juhlin L, Olsson MJ. British J Dermatology 1996; 135: 852.
  27. Egna melanocyter ger ny pigmentering. Olsson MJ, Juhlin L. Läkartidningen 1995; 92: 1341-1344.
  28. Transplantation of melanocytes in vitiligo. Olsson MJ, Juhlin L. Br J Dermatol 1995; 132: 587-591.
  29. Ca2+-Induced Ca2+ Oscillations in Parathyroid Cells. Ridefelt P, Björklund E, Åkerström G, Olsson MJ, Rastad J, Gylfe E. Biochem and Biophys Res Commun 1995; 215: 903-909.
  30. Transplantation von Melanozyten bei Vitiligo. Olsson MJ, Juhlin L. Zeitschrift für Haut- und Geschlechtskrankheiten 1995; 4(70): 283-286.
  31. Repigmentation of Vitiligo by autologous melanocytes. Olsson MJ, Juhlin L. Dermatology Digest 1994; May: 29-30.
  32. Olsson MJ, Juhlin L. Acta Derm Venereol (Stockh) 1994; 74: 148.
  33. Vitiligo: Repigmentation with cultured melanocytes after cryostorage. Olsson MJ, Moellmann G, Lerner AB, Juhlin L. Acta Derm Venereol (Stockh) 1994; 74: 226-228.
  34. Pigment cell transplantation for treatment of vitiligo: a progress report. Löntz W, Olsson MJ, Moellmann G, Lerner AB. J Am Acad Dermatol 1994; 30(4): 591-597.
  35. Transplantation and surgical treatment of parkinsonian syndromes. Widner H, Rehncrona S. Curr Opin Neurol Neurosurg. 1993 Jun;6(3):344-9.
  36. Repigmentation of vitiligo by transplantation by cultured autologous melanocytes. Olsson MJ, Juhlin L. Acta Derm Venerol (Stockh) 1993; 72: 49-51.
  37. Repigmentation in vitiligo by pigment cell transplantation. Olsson MJ, Juhlin L, Lerner AB. Pigment Cell Res 1993; 6: 286.
  38. Biosynthesis of 3,4-didehydroretinol from retinol by human skin keratinocytes in culture. Rollman O, Wood EJ, Olsson MJ, Cunliffe WJ. Biochem J 1993; 293: 675-682.
  39. Fifteen months’ follow-up on bilateral embryonic mesencephalic grafts in two cases of severe MPTP-induced parkinsonism. Widner H, Tetrud J, Rehncrona S, Snow BJ, Brundin P, Björklund A, Lindvall O, Langston JW. Adv Neurol. 1993;60:729-33.
  40. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Widner H, Tetrud J, Rehncrona S, Snow B, Brundin P, Gustavii B, Björklund A, Lindvall O, Langston JW. N Engl J Med. 1992 Nov 26;327(22):1556-63.
  41. Melanocyte transplantation in vitiligo. Olsson MJ, Juhlin L. Lancet 1992; 340:981.
  42. Transplantation of fetal dopamine neurons in Parkinson’s disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants. Sawle GV, Bloomfield PM, Björklund A, Brooks DJ, Brundin P, Leenders KL, Lindvall O, Marsden CD, Rehncrona S, Widner H, et al. Ann Neurol. 1992 Feb;31(2):166-73.
  43. Transplantation of fetal dopamine neurons in Parkinson’s disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Lindvall O, Widner H, Rehncrona S, Brundin P, Odin P, Gustavii B, Frackowiak R, Leenders KL, Sawle G, Rothwell JC, et al. Ann Neurol. 1992 Feb;31(2):155-65.
  44. Transplanted allogeneic fetal dopamine neurons survive and improve motor function in idiopathic Parkinson’s disease. Widner H, Brundin P, Rehncrona S, Gustavii B, Frackowiak R, Leenders KL, Sawle G, Rothwell JC, Marsden CD, Björklund A, et al. Transplant Proc. 1991 Feb;23(1 Pt 1):793-5.
  45. In reply: fetal brain grafts and Parkinson’s disease. Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, Frackowiak R, Leenders KL, Sawle G, Rothwell JC, Marsden CD, Björklund A. Science. 1990 Dec 7;250(4986):1435.
  46. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson’s disease. Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, Frackowiak R, Leenders KL, Sawle G, Rothwell JC, Marsden CD, et al. Science. 1990 Feb 2;247(4942):574-7.
  47. Neural transplantation in Parkinson’s disease: the Swedish experience. Lindvall O, Rehncrona S, Brundin P, Gustavii B, Astedt B, Widner H, Lindholm T, Björklund A, Leenders KL, Rothwell JC, et al. Prog Brain Res. 1990;82:729-34.
  48. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson’s disease. A detailed account of methodology and a 6-month follow-up.Lindvall O, Rehncrona S, Brundin P, Gustavii B, Astedt B, Widner H, Lindholm T, Björklund A, Leenders KL, Rothwell JC, Frackowiak R, Marsden D, Johnels B, Steg G, Freedman R, Hoffer BJ, Seiger A, Bygdeman M, Strömberg I, Olson L. Arch Neurol. 1989 Jun;46(6):615-31.
  49. Fetal dopamine-rich mesencephalic grafts in Parkinson’s disease. Lindvall O, Rehncrona S, Gustavii B, Brundin P, Astedt B, Widner H, Lindholm T, Björklund A, Leenders KL, Rothwell JC, Frackowiak R, Marsden CD, Johnels B, Steg G, Freedman R, Hoffer BJ, Seiger L, Strömberg I, Bygdeman M, Olson L. Lancet. 1988 Dec 24-31;2(8626-8627):1483-4.